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Introduction
Differences in structure and in vitro properties of anti-
TNF agents may account for different modes of action
and clinical outcomes. The activities of certolizumab
pegol (CZP), etanercept (ETA), infliximab (IFX) and
adalimumab (ADA) have been compared using in vitro
assays [1]. However, golimumab (GLM) has not pre-
viously been evaluated.
Aim
To compare the activity of CZP with other anti-TNFs,
including GLM, in a range of in vitro assays.
Methods
Neutralisation of human TNF was assessed in the L929
bioassay. The activity of anti-TNFs at inhibiting LPS-
driven IL-1b secretion by monocytes was measured by
ELISA. To determine apoptosis induction, activated per-
ipheral blood lymphocytes and monocytes were examined
by Annexin V staining using flow cytometry. The effect on
neutrophil necrosis was measured by myeloperoxidase
release. An isotype-matched control was used in all assays
except the L929 bioassay.
Results
The IC90 neutralisation activity in the L929 bioassay was
0.3 ng/mL for ETA, 4 ng/mL for GLM, 15 ng/mL for
ADA, and 20 ng/mL for IFX, versus 2.5 ng/mL for
CZP. CZP was the most potent inhibitor of LPS-driven
IL-1b secretion (IC50 ~0.1 ng/mL), followed by GLM
(20 ng/mL).
GLM, ADA, IFX and ETA induced apoptosis of
monocytes and lymphocytes to a similar degree.
CZP caused no increase in apoptosis above isotype-
matched control levels. In the neutrophil necrosis assay,
ADA, IFX and GLM caused ~70% necrosis at 100 μg/mL,
and ETA 48%. CZP did not increase the level of necrosis
above the level of the control.
Conclusion
The ability of GLM, IFX, and ADA to neutralise human
TNF was inferior to CZP and ETA. CZP had a different
profile to the other anti-TNFs; it was the most potent at
inhibiting monocyte LPS-driven IL-1b production, did
not induce apoptosis of activated monocytes and lym-
phocytes, and did not cause neutrophil necrosis. The
clinical relevance of these i nv i t r oe f f e c t si su n k n o w n .
Nevertheless, these assays show interesting differences
between anti-TNFs.
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